1606 Corp. Signs Letter of Intent to Acquire Stake in Adnexus

1606 Corp. (OTC Pink: CBDW), a leader in AI technology development, has announced a nonbinding Letter of Intent (LOI) to acquire a strategic stake in Adnexus. Adnexus is a pioneering company in AI innovations for early drug discovery and infectious disease research.

This potential investment highlights 1606 Corp.'s dedication to expanding its technological capabilities in AI. Integrating Adnexus's research and development could enhance 1606 Corp.'s portfolio, especially in healthcare and biotech.

Adnexus is noted for its work in AI-driven drug discovery and treatments for diseases like HIV and SARS-COV-2. The alliance aims to speed up innovation in healthcare, merging 1606 Corp.'s strengths in conversational AI with Adnexus's research.

CEO Austen Lambrecht expressed enthusiasm about the agreement, noting it aligns well with 1606 Corp.'s vision. The transaction is subject to due diligence and standard conditions in the LOI. Both companies expect the partnership to generate significant shareholder value.